Breaking News
March 25, 2018 - Humanigen Completes Enrollment of Phase 1 Clinical Trial of Lenzilumab for Treatment of Chronic Myelomonocytic Leukemia
March 25, 2018 - ENDO 2018 Roundup: New Tx Options for Obesity, Low BMD, Benign Thyroid Disease
March 25, 2018 - The protein that prevents loose teeth
March 24, 2018 - Morning Break: Skip the Finger Exam? Self C-Section; Toxic Toenail Fungus
March 24, 2018 - 3-D simulations reveal synergistic mechanisms of the human heart
March 24, 2018 - Newly designed three-part molecule shows promise to treat breast cancers
March 24, 2018 - Pubertal hormones not responsible for changes in social behavior during adolescence
March 24, 2018 - Waning Vaccine Protection May Be Driving Rise in U.S. Mumps Cases
March 24, 2018 - Folic Acid in Utero Tied to Food Allergy Risk
March 24, 2018 - Trial shows safety of drugs for irregular heartbeat patients undergoing treatment
March 24, 2018 - Penn State psychologists shed light on false memories in older adults
March 24, 2018 - Patients who self-discharge should be viewed more positively, say researchers
March 24, 2018 - Wearable brain scanner enables brain imaging whilst moving
March 24, 2018 - Trump Signs $1.3 Trillion Spending Bill, Averts Shutdown
March 24, 2018 - Two drugs prevent heart problems in breast cancer patients
March 24, 2018 - Research provides better understanding of how some cancer cells resist treatment
March 24, 2018 - Certain nutrients found in food may help reduce symptoms of psychotic illness
March 24, 2018 - AbbVie Announces Positive Topline Results from Second Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids
March 24, 2018 - AHRQ Is in Trouble | Medpage Today
March 24, 2018 - Could a pap test spot more than just cervical cancer?
March 24, 2018 - Men have greater hospital readmission risk following firearm injury, study shows
March 24, 2018 - Pediatric psychologist shares 11 warning signs of childhood depression
March 24, 2018 - OncoBreak: ‘I Was Normal Once’; Ending Cervical Cancer; Mammo Controversy
March 24, 2018 - Gum Disease by the Numbers
March 24, 2018 - Studies show tool can identify individual needs, supports to help youths with autism, intellectual disabilities
March 24, 2018 - Study reveals cause of extreme nausea in pregnancy
March 24, 2018 - New findings highlight need to reconsider cervical cancer screening guidelines
March 24, 2018 - Smartwatch App Might Help Detect A-Fib
March 24, 2018 - TAVR Reasonable for Low-Flow, Low-Gradient Aortic Stenosis
March 24, 2018 - Kids with severe brain injuries may develop ADHD: study
March 24, 2018 - Researchers explore ways to help older adults taper off and stop using sedatives
March 24, 2018 - Back pain being mismanaged globally
March 24, 2018 - Fingerprint test accurately and noninvasively detects heroin, cocaine users
March 24, 2018 - Leading experts to promote cardiovascular health at EuroPrevent 2018
March 24, 2018 - A Role for Rituximab in Lupus?
March 24, 2018 - New osteoarthritis genes discovered
March 24, 2018 - Maternal intake of DHA supplement linked to higher fat-free body mass in children
March 24, 2018 - Royal College of Pathologists‘ bulletin provides summary of Tissue Handling Workshop
March 24, 2018 - Maternal alcohol use early in pregnancy may be risk factor for infant abdominal malformation
March 24, 2018 - Savara Initiates Phase 2a Clinical Study of Molgradex for the Treatment of NTM Lung Infection
March 24, 2018 - Accelerated WBI Should be the Norm for Most Breast Cancers
March 24, 2018 - Experts seek to standardize treatments for childhood rheumatic diseases
March 24, 2018 - Foil-based measuring chip rapidly detects Legionella
March 24, 2018 - Bariatric surgery linked to positive outcomes in very obese adolescents with type 2 diabetes
March 24, 2018 - Researchers identify chemical responsible for carcinogen formation in recycled wastewater
March 24, 2018 - Obesity and severe obesity continue to rise among U.S. adults
March 24, 2018 - Missed hospital appointments increase after spring clock change in the UK
March 24, 2018 - Researchers explore ways to manage and prevent falls in older adults with dementia
March 24, 2018 - Are there risks from secondhand marijuana smoke? Early science says yes.
March 24, 2018 - NUST MISIS researchers produce elastic metal rods for scoliosis treatment
March 24, 2018 - New University of Bath project seeks to make injections safer
March 24, 2018 - Higher-dose RT does not improve survival but reduces recurrence risk for prostate cancer patients
March 24, 2018 - Researchers examine link between knee pain and depression in older adults
March 24, 2018 - FDA Alert: BD Vacutainer Blood Collection Tubes by Becton, Dickinson and Company (BD): Class I Recall
March 24, 2018 - Daytime Sleepiness Linked to Amyloid Accumulation Without Dementia
March 24, 2018 - Energy storehouses in the brain may be source of Alzheimer’s, targets of new therapy
March 24, 2018 - Praising people with autism shows promise for producing more exercise
March 24, 2018 - Using harmless red or infrared light to diagnose breast cancer
March 24, 2018 - Clash over abortion hobbles a health bill. Again. Here’s how.
March 23, 2018 - Virtual nature environment could be new way to recover from stress
March 23, 2018 - New study identifies key cellular mechanisms behind vascular aging in mice
March 23, 2018 - Nightmares Common Among U.S. Troops, But Seldom Reported
March 23, 2018 - Another Record Low for Tuberculosis in U.S.
March 23, 2018 - Changes in the eye connected to a decline in memory
March 23, 2018 - Radiologist creates dramatic teaching tool using power of VR
March 23, 2018 - Grilled meat could be raising the risk of hypertension finds study
March 23, 2018 - Mutations found in bassoon gene may help explain cause of rare brain disorder
March 23, 2018 - Childhood Brain Injuries May be Linked to ADHD Years Later
March 23, 2018 - Why treating addiction with medication should be carefully considered
March 23, 2018 - Researchers make key discovery about cellular pathway linked to myriad of diseases
March 23, 2018 - Researchers uncover cause of rare childhood neurodegenerative disease
March 23, 2018 - Measles infection in early childhood could contribute to later COPD
March 23, 2018 - Opioid painkiller is top prescription in 11 states
March 23, 2018 - Sienna Biopharmaceuticals Announces First Patient Dosed In Proof-of-Concept Trial of Topical By Design™ JAK Inhibitor SNA-125 for Atopic Dermatitis
March 23, 2018 - In Teen Girls, Neural Patterns May Drive Emotional Resilience
March 23, 2018 - Gene-based test for urine detects, monitors bladder cancer
March 23, 2018 - BD to introduce new digital solution for IV chemotherapy administration process at EAHP 2018
March 23, 2018 - New computational method helps to identify tumor cell mutations with greater accuracy
March 23, 2018 - Researchers identify potential obesity treatment in freezing hunger-signaling nerve
March 23, 2018 - Wales participates in the 100,000 Genomes Project
Tocilizumab Benefits Persist in SSc

Tocilizumab Benefits Persist in SSc

image_pdfDownload PDFimage_print

Action Points

  • Clinically meaningful improvements in systemic sclerosis among patients treated with subcutaneous tocilizumab (Actemra) persisted during the open-label phase of a multinational randomized phase II trial.
  • The most common adverse events in this study were infections, as has been seen in clinical trials of tocilizumab in rheumatoid arthritis.

Clinically meaningful improvements in systemic sclerosis among patients treated with subcutaneous tocilizumab (Actemra) persisted during the open-label phase of a multinational randomized phase II trial, researchers reported.

At week 48, the conclusion of the double-blind phase of a study known as faSScinate, change from baseline on the modified Rodnan skin score was -5.6 (95% CI -8.9 to -2.4) among patients who were receiving tocilizumab, according to Dinesh Khanna, MD, of the University of Michigan in Ann Arbor, and colleagues.

By week 96, additional decreases were seen on skin scores, bringing the total improvement to a score of -9.1 (95% CI -12.5 to -5.6).

Meanwhile, patients who had been randomized to placebo for the first 48 weeks had a change from baseline in Rodnan skin scores of -3.1 (95% CI -5.4 to -0.9), but by week 96, after 48 weeks of open-label tocilizumab, mean change in score was -9.4 (95% CI -11.8 to -7), the investigators reported online in Annals of the Rheumatic Diseases.

The differences at week 48, while clinically meaningful, were not statistically significant, they noted.

Morbidity and mortality are high among patients with systemic sclerosis, particularly among those with lung involvement, and few treatment options are available. Cyclophosphamide has been used for pulmonary disease, but is associated with significant toxicity, and stem cell transplantation has improved skin fibrosis and lung function but is associated with risks and high costs.

The rationale for using tocilizumab, a monoclonal antibody targeting the interleukin (IL)-6 receptor-α, is that IL-6 is thought to be involved in the pathogenesis of SSc, with patients having increased IL-6 expression in endothelial cells and elevations of IL-6 in serum.

The faSScinate study was conducted in 35 centers in North America and Europe, enrolling 87 patients with active disease of less than 5 years’ duration. The majority were white women, and baseline total modified Rodnan skin score was about 25. The treatment consisted of subcutaneous injections of tocilizumab, 162 mg, once weekly.

At week 48, 30 (69.8%) of the patients originally randomized to tocilizumab entered the open-label phase, as did 31 (70.5%) of those who received placebo in the blinded phase. The full 96-week study was completed by 27 (62.8%) of those who had been on active treatment throughout and by 24 (54.5%) of those originally given placebo.

By week 96, a total of 27 patients who had been on continuous tocilizumab (during the placebo-controlled phase and the open-label phase) had achieved the minimal clinically important difference on the skin score of a change of at least 4.7 units, as had 24 of those in the placebo-tocilizumab group.

For lung function, similar proportions of patients in the continuous tocilizumab and placebo-tocilizumab experienced absolute decreases in percent predicted forced vital capacity in the open-label phase (46% and 42%, respectively), whereas during the double-blind phase, 54% of the tocilizumab group experienced any worsening compared with 83% of those in the placebo group.

Improvements also were seen on patient-reported outcomes by week 96 for both continuous tocilizumab and placebo-tocilizumab groups. For instance, on the Health Assessment Questionnaire Disability Index, changes from baseline were -0.13 and -0.29, respectively.

The most common adverse events in this study were infections, as has been seen in clinical trials of tocilizumab in rheumatoid arthritis. However, “rates of serious adverse events and serious infections in this study in patients with SSc were approximately five times and eight times higher, respectively, than those reported in patients with rheumatoid arthritis, which is expected given the high morbidity and mortality in patients with SSc,” the authors wrote.

In particular, patients with SSc are prone to develop digital ulcers, and two patients had infected digital ulcers and one had osteomyelitis.

The investigators emphasized that the study was not powered for a statistical comparison of efficacy during the open-label phase, noting that a phase III randomized controlled trial (NCT02453256) including more than 200 patients is underway.

They concluded that tocilizumab was beneficial for skin and lung manifestations of SSc, and “may be a promising targeted therapy for patients with progressive SSc who have few treatment options.”

Limitations of the study were its open-label design after week 48 and a high discontinuation rate. In addition, patients who completed the 48-week blinded phase and entered the open-label phase may have been healthier, so selection bias was possible.

The study was funded by Roche.

The authors reported financial relationships with Roche, Actelion, Boehringer-Ingelheim, Covis, CSL Behring, Corbus, Cytori, EMD Serono, Genentech/Roche, GlaxoSmithKline, Inventiva, Medac, Sanofi-Aventis, UCB, Bristol-Myers Squibb, Bayer, Pfizer, Eicos Sciences, AstraZeneca, Eli Lilly, Galapagos, Servier, Sandoz, and Chugai. Several are employees of Roche or Genentech.

  • Reviewed by
    Robert Jasmer, MD Associate Clinical Professor of Medicine, University of California, San Francisco and Dorothy Caputo, MA, BSN, RN, Nurse Planner


Tagged with:

About author

Related Articles